Hypnosedatives in the elderly: A guide to appropriate use

CNS Drugs

Volumn 11, Issue 4, 1999, Pages 263-279

  Woodward, Michael ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHLORAL HYDRATE; CLOMETHIAZOLE; HYPNOTIC SEDATIVE AGENT; MELATONIN; NEUROLEPTIC AGENT; PARALDEHYDE; TRYPTOPHAN; ZOLPIDEM; ZOPICLONE;

ADVERSE DRUG REACTION; AGED; ANXIETY NEUROSIS; BREATHING DISORDER; CLINICAL TRIAL; CONFUSION; DEMENTIA; DRUG METABOLISM; DRUG WITHDRAWAL; HANGOVER; HUMAN; INSOMNIA; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; WITHDRAWAL SYNDROME;

EID: 0032920466     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911040-00003     Document Type: Review

References (120)

1. 1. Wysowski DK, Baum C. Patient use of prescription sedative -Hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med 1991; 151: 1779-83
2. 2. Walsh JK, Engelhardt CL. Trends in the pharmacological treatment of insomnia. J Clin Psychol 1992; 53 (Dec Suppl.): 10-7
3. 3. Olfson M, Pincus HA. Use of benzodiazepines in the community. Arch Intern Med 1994; 154: 1235-40
4. 4. Baum C, Kennedy DL, Knapp DE, et al. Prescription drug use in 1984 and changes over time. Med Care 1988; 26: 105-14
5. 5. Lockwood A, Berbatis CG. Psychotropic drugs in Australia: consumption pattern. Med J Aust 1990; 153: 604-11
6. 6. Brayley J, Bradshaw G, Pols R. Guidelines for the prevention and management of benzodiazepine dependence. National Health and Medical Research Council Monograph Series No. 3. Canberra, Australia: Australian Government Printing Service, 1991
7. 7. Lyndon R, Russell J. Can overuse of psychotropic drugs by the elderly be prevented? Aust NZ J Psychol 1990; 24: 77-81
8. 8. Howes JB, Ryan J, Fairbrother G, et al. Benzodiazepine prescribing in a Sydney teaching hospital. Med J Aust 1996; 165: 305-8
9. 9. Spore D, Mor V, Hiris J, et al. Psychotropic use among older residents of board and care facilities. J Am Geriatr Soc 1995; 43: 1403-9
10. 10. Beardsley RS, Larson DB, Burns BJ, et al. Prescribing of psychotropics in the elderly nursing home patient. J Am Geriatr Soc 1989; 36: 327-30
11. 11. Waldron T. Increased prescribing of valium, librium and other drugs - an example of the influence of economic and social factors on the practice of medicine. Int J Health Serv 1977; 7: 37-62
12. 12. Rodrigo EK, King MB, Williams P. Health of long-term benzodiazepine users. BMJ 1988; 296: 603-6
13. 13. Shorr RI, Robin DW. Rational use of benzodiazepines in the elderly. Drugs Aging 1994; 4: 9-20
14. 14. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutics consideration. Clin Pharmacokinet 1991; 21: 165-77; 262-73
15. 15. du Souich P, Verges J, Erill S. Plasma protein binding and pharmacological response. Clin Pharmacokinet 1993; 24: 435-40
16. 16. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450 - linked drug metabolism in humans: an analysis of 226 subject with equal histopathological conditions. Clin Pharmacol Ther 1997; 61: 331-9
17. 17. Woodhouse KW, James OFW. Hepatic drug metabolism and ageing. Br Med Bull 1990; 46: 22-35
18. 18. Schmucker DR, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48: 365-74
19. 19. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275-83
20. 20. Greenblatt DJ, Divoll M, Abernethy DR, et al. Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev 1983; 14: 251-92
21. 21. Greenblatt DJ, Divoll M, Harmatz JS, et al. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 1981; 30: 475-86
22. 22. Klotz H, Arvant GR, Hoyumpa A, et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975; 55: 347-59
23. 23. Kruse WHM. Problems and pitfalls in the use of benzodiazepines in the elderly. Drug Saf 1990; 5: 328-44
24. 24. Cook PJ, Flanagan R, James IM. Diazepam tolerance: effect of age, regular sedation, and alcohol. BMJ 1984; 289: 351-3
25. 25. Pomara N, Stanley B, Block R, et al. Increased sensitivity of the elderly to the central depressant effects of diazepam. J Clin Psychol 1985; 46: 185-7
26. 26. Pomara N, Deptula D, Medel M, et al. Effects of diazepam on recall memory: relationship to ageing, dose and duration of treatment. Psychopharmacol Bull 1989; 25: 144-8
27. 27. Castleden CM, George CF, Marcer D, et al. Increased sensitivity to nitrazepam in old age. BMJ 1977; 1: 10-2
28. 28. Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: a review. Anaesthesiology 1990; 72: 926-38
29. 29. Swift CG, Swift MR, Hamley J, et al. Side-effect 'tolerance' in elderly long-term recipients of benzodiazepine hypnotics. Age Aging 1987; 13: 335-43
30. 30. Rummans TA, Davis LJ, Morse RM. Learning and memory impairment in older, detoxified diazepine-dependent patients. Mayo Clin Proc 1993; 68: 731-7
31. 31. Nikaido AM, Ellinworth Jr EH, Heatherly DG, et al. Differential CNS effects of diazepam in elderly adults. Pharmacol Biochem Behav 1987; 27: 273-81
32. 32. Swift CG, Ewen JM, Clarke P. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol 1985; 29: 111-8
33. 33. Cutson TM, Gray SL, Hughes MA. Effect of a single dose of diazepam on balance measures in older people. J Am Geriatr Soc 1997; 43: 435-40
34. 34. Larson EB, Kukull WA, Buchner D, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987; 107: 169-73
35. 35. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fractures. N Engl J Med 1987; 316: 363-9
36. 36. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half life and the risk of hip fracture. JAMA 1989; 262: 3303-7
37. 37. Neutel CI, Hirdes JP, Maxwell CJ. New evidence on benzodiazepine use and falls: the time factor. Age Aging 1996; 25: 273-8
38. 38. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988; 319 (26): 1701-7
39. 39. Hering RMC, Stricker BH, Deboer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Arch Intern Med 1995; 155: 1801-7
40. 40. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992; 136: 873-83
41. 41. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352 (9137): 1331-6
42. 42. Zisselman MH, Rovner BW, Yuen EJ, et al. Sedative-hypnotic use and increased hospital stay and costs in older people. J Am Geriatr Soc 1996; 44: 1371-4
43. 43. Kripke DF, Simons RN, Garfinkel L, et al. Short and long sleep and sleeping pills. Is increased mortality associated? Arch Gen Psychiatry 1979; 36: 103-16
44. 44. Ried LD, Johnson RE, Gettman DA. Benzodiazepinc exposure and functional status in older people. J Am Geriatr Soc 1998; 46 (1): 71-6
45. 45. Ashton M. Guidelines for the rational use of benzodiazepines. Drugs 1994; 48: 25-40
46. 46. Petursson H, Lader MH. Benzodiazepine dependence. Br J Addict 1981; 76: 133-45
47. 47. Woods JM, Katz JL, Winger G. Abuse liability of benzodiazepines. Pharmacol Rev 1987; 39: 251-419
48. 48. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse and consequences. Pharmacol Rev 1992; 44: 151-347
49. 49. Tyrer P. Withdrawal from hypnotic drugs. BMJ 1993; 306: 706-8
50. 50. Lader MH, Petursson H. Benzodiazepine derivatives - side-effects and dangers. Biol Psychiatry 1981; 16: 1195-201
51. 51. Schweizer E, Case G, Rickels K. Benzodiazepine dependence and withdrawal in elderly patients. Am J Psychiatry 1989; 146: 529-31
52. 52. Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict 1987; 82: 665-71
53. 53. Kerr JS, Dawe RA, Parkin C, et al. Zopiclone in elderly patients: efficacy and safety. Hum Psychopharmacol 1995; 10: 221-9
54. 54. Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1988; 55: 277-302
55. 55. Inman W, Kubota K, Pearce G, et al. PEM Report Number 10. Zopiclone. Pharmacoepidemiol Drug Saf 1993; 2: 499-521
56. 56. Brynes JJ, Greenblatt DJ, Miller LG. Benzodiazepine receptor binding of nonbenzodiazepines in vitro: alpidem, zolpidem and zopiclone. Brain Res Bull 1992; 29: 905-8
57. 57. Berlin I, Warol D, Hergueta T et al. Comparison of the effects of zolpidem and triuzolam on memory functions, psychomotor performances, and postural sway in healthy subject. J Clin Psychopharm 1993; 13: 100-6
58. 58. Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory and performance effects of hypnotics. Psychopharmacology 1994; 116: 130-4
59. 59. Rush CR, Griffiths RR. Zolpidem, triazolam and temazepam: behavioural and subject - rated effects in normal volunteers. J Clin Psychopharm 1996; 16: 146-59
60. 60. Mintzer M, Frey JM, Yingling JE, et al. Triazolam and zolpidem: a comparison of their psychomotor, cognitive and subjective effects in healthy volunteers. Behav Pharmacol 1997; 8: 561-74
61. 61. Hoehns JD, Perry PJ. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993; 12: 814-28
62. 62. Langtry HD, Benfield P, Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990; 40: 291-313
63. 63. Kummer J, Guendel L, Linden J, et al. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric inpatients with insomnia. J Int Med Res 1993; 21: 171-84
64. 64. Mattila M, Seppala T, Mattila MJ. Combined effects of buspirone and diazepam on objective and subjective tests of performance in healthy volunteers. Clin Pharmacol Ther 1986; 40: 620-6
65. 65. Greenblatt DJ, Harmatz JS, Gouthro T, et al. Distinguishing a benzodiazepine agonist (triazolam) from a monagonist anxiolytic (buspirone) by elcetroencephalography: kinetic - dynamic studies. Clin Pharmacol Ther 1994; 56: 100-11
66. 66. Lader M. Can buspirone induce rebound, dependence or abuse? Br J Psychiatry 1991; 159 Suppl. 12: 45-51
67. 67. Goa KL, Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114-29
68. 68. Arendl J. Melatonin. Clin Endocrinol 1988; 29: 205-29
69. 69. Caranasos GC. Sleep disorders. In: Ham R, editor. Geriatric medicine annual. Bradell: NJ Medical Economics, 1987: 135-59
70. 70. Woodward MC. The management of insomnia in older people. Aust J Hosp Pharm 1996; 26: 462-5
71. 71. Mellinger GD, Balten MB, Uhlentrulh EH. Insomnia and its treatment. Arch Gen Psychiatry 1985; 42: 225-32
72. 72. Weyerer A, Dilling M. Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study. Sleep 1991; 14: 392-8
73. 73. McDowell JA, Mion LC, Lydon TJ, et al. A nonpharmacological sleep protocol for hospitalized older patients. J Am Geriatr Soc 1998; 46 (6): 700-5
74. 74. Campbell SS, Dawson D, Anderson MW. Alleviation of sleep maintenance insomnia with timed exposure to bright light. J Am Geriatr Soc 1993; 41: 829-36
75. 75. Haimov I, Laudon M, Zisapel N, et al. Sleep disorders and melatonin rhythms in elderly people [research report]. BMJ 1994; 309 (6948): 167
76. 76. Weiss KJ. Optimal management of anxiety in older patients. Drugs Aging 1996; 9: 191-201
77. 77. Shader RI, Greenblatt MD. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993; 328: 1398-405
78. 78. Anon. Zopiclone: an acceptable alternative to benzodiazepines. Drug Ther Perspect 1993; 2: 4-6
79. 79. Divoll M, Greenblatt DJ, Harmatz JS, et al. Effects of age and gender disposition on temazepam. J Pharmacol Sci 1981; 70: 104-7
80. 80. Smith RB, Divoli M, Gillespe WR, et al. Effects of subject age on the pharmacokinetics nf oral triazolam and temazepam. J Clin Psychopharmacol 1983; 3: 172-6
81. 81. Greenblatt DJ, Harmatz JS, Engelhardt N, et al. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Arch Gen Psych 1989; 46: 326-32
82. 82. Kales A, Soldatos CR, Bixler EO, et al. Early morning insomnia with rapidly eliminated benzodiazepines. Science 1983; 220: 95-7
83. 83. Kales A, Manfredi RL, Vgontzas AN, et al. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther 1991; 46: 468-76
84. 84. Patterson JF. Triazolam syndrome in the elderly. South Med J 1987; 80: 1425-6
85. 85. Cowley G, Springer K, Iarovici D, et al. Sweet dreams or nightmares? Newsweek 1991; August: 44
86. 86. Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691-8
87. 87. Jonas JM. Idiosyncratic side effects of short half-life benzodiazepine hypnotics: fact or fancy? Hum Psychopharmacol 1992; 7: 205-16
88. 88. Mamelek M, Csima A, Buck L, et al. A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol 1989; 9: 260-7
89. 89. Kales A, Soldatos CR, Bixler EO. Diazepam effects on sleep and withdrawal phenomenon. J Clin Psychopharmacol 1988; 8: 340-6
90. 90. Lemoine P, Allain H, Janus C, et al. Gradual withdrawal of zopiclone (7.5mg) and zolpidem (10mg) in insomniacs treated for at least three months. Eur Psychiatry 1995; 10 Suppl. 3: 161-5
91. 91. Carskadon MA, Seidel WF, Greenblatt DJ, et al. Daytime carry-over of triazolam and flurazepam in elderly insomniacs. Sleep 1982; 5: 361-71
92. 92. Grad RM. Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. J Fam Pract 1995; 41: 473-81
93. 93. Hollister LE, Müller-Oerlinghausen B, Rickels K, et al. Clinical Uses of Benzodiazepines. J Clin Psychopharmacol 1993; 13 Suppl. 1 :1S-169S
94. 94. Agnoli A, Manna V, Murtucci N. Double-blind study on the hypnotic and antianxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia. Int J Clin Pharmacol Res 1989; 9: 277-81
95. 95. Committee on the reviews of Medicines. Systematic review of the benzodiazepines. BMJ 1980; 1: 910-2
96. 96. Ankier SI, Goa KL. Quazepam: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs 1980; 35 (1): 42-62
97. 97. Agnini E, Parravicini L, Bamonte F, et al. Pharmacological studies with quazepam, a new benzodiazepine hypnotic. Arzneimittelforschung 1982; 32: 1456-9
98. 98. Barnett A, Iorio LC, Ongini E. The sedative-hypnotic properties of quazepam, a new hypnotic agent. Arzneimittelforschung 1982; 32: 1452-5
99. 99. Garfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly people by controlled-rclcase melatonin. Lancet 1995; 346: 541-4
100. 100. Haimov I, Lavie P. Potential of melatonin replacement therapy in older patients with sleep disorders. Drugs Aging 1995; 7: 75-8
101. 101. Schlich D, L'Heritier C, Coquelin JP. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 1991; 19: 271-9
102. 102. Kales A, Bixler EO, Kales JD, et al. Comparative effectiveness of nine hypnotic drugs: sleep laboratory studies. J Clin Pharmacol 1977; 17: 207-13
103. 103. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychol 1991; 52: 16-23
104. 104. Hecker R, Burr M, Newbury G. Risk of benzodiazepine dependence resulting from hospital admission. Drug Alcohol Rev 1992; 11: 131-5
105. 105. Shorr RI, Bauwens S, Landefeld CS. Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: placing the elderly at risk. Am J Med 1990; 89: 725-31
106. 106. Woodward MC. Drug prescribing for older people - can we get it right [commentary]? Aust J Ageing 1994; 13: 27
107. 107. Woodward MC. (Convenor of expert panel). Medication and the older person. National Health and Medical Research Council. Series of clinical management in the elderly. No. 7. Canberra, Australia: Australian Government Printing Service, 1994
108. 108. Gilbert A, Innes JM, Owen N, et al. Trial of an intervention to reduce chronic benzodiazepine use among residents of aged-care accommodation. Aust NZ J Med 1993; 23: 343-7
109. 109. Griffith DNW, Robinson M. Prescribing practice and policy for hypnotics: a model of pharmacy audit. Age Aging 1996; 25: 490-2
110. 110. Batty GM, Oborne CA, Swift CG. Reduction in inappropriate prescribing of benzodiazepines by verbal multidisciplinary intervention [abstract P274]. J Am Geriat Soc 1997; 45: S80
111. 111. Weintraub M, Singh S, Byrne L, et al. Consequences of the 1989 New York State triplicate henzodiazcpine prescription regulations. JAMA 1991; 266: 2392-7
112. 112. Shader RI, Greenblatt DJ, Balter MB. Appropriate use and regulatory control of benzodiazepine. J Clin Pharmacol 1991; 31: 781-4
113. 113. Stoppe G, Sandwlzer H, Staedt J, et al. Sleep disturbances in the demented elderly: treatment in ambulatory care. Sleep 1995; 18: 844-8
114. 114. Shelton PS, Hocking LB. Zolpidem for dementia-related insomnia and night-time wandering. Ann Pharmacother 1997; 31: 319-22
115. 115. Murciano P, Armengaud MH, Cramer PH, et al. Acute effects of zolpidem, triazolam and flunitrazepam on arterial blood gases and control of breathing in severe COPD. Eur Respir J 1993; 6: 625-9
116. 116. Camacho ME, Morin CM. The effect of temazepam on respiration in elderly insomniacs with mild sleep apnoea. Sleep 1995; 18: 644-5
117. 117. Schnelle JF, Ouslander JG, Simmons F, et al. Night-time sleep and bed mobility among incontinent nursing home residents. J Am Geriatr Soc 1993; 41: 903-9
118. 118. Woo E, Proulx SM, Greenblatt DJ. Differential side-effect profile of triazolam versus flurazepam in elderly patients undergoing rehabilitation therapy. J Clin Pharmacol 1991; 31: 168-73
119. 119. Salzman C, editor. Clinical geriatric psychopharmacology. 3rd ed. Baltimore: Williams and Wilkins, 1998
120. 120. Nelson JC, editor. Geriatric psychopharmacology. New York: Marcel Dekker, 1998